Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 659

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 659
---
 |    1,097,599 |     |  1,140,465 |     | 1,032,078 |     |        9,087 |
| CIBIC (Line 2)        |     | 10/1/2023  |     | 10/1/2028  |     |      6.5 | % |     | US$      |     |      238,742 |     |    255,743 |     |   247,919 |     |            — |
| BIOCERES (Line 1)     |     | 01/17/2023 |     | 01/17/2028 |     |      6.5 | % |     | US$      |     |      777,511 |     |    839,917 |     |   597,846 |     |       42,489 |
| BIOCERES (Line 2)     |     | 09/1/2023  |     | 09/1/2028  |     |      6.5 | % |     | US$      |     |      155,405 |     |    160,378 |     |   140,466 |     |        1,738 |
| Total Borrowings      |     |            |     |            |     |          |   |     |          |     |              |     |  3,151,436 |     | 2,661,008 |     |              |

Outstanding balance and transaction with other related party: Cibic Since inception the Company commercializes its Diagnostics services through an exclusive commercialization agreement with CIBIC, one of the shareholders of Heritas Ltd, the parent company of the Company.

|                   |     |        As of 
 December 31, 
         2024 |     |    As of 
 June 30, 
     2024 |
|:------------------|:----|-------------:|:----|---------:|
| Trade receivables |     |      248,504 |     |   18,056 |
| Trade payables    |     |       12,864 |     |   21,024 |

F-113

Notes to Unaudited Interim Condensed Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 20.Related parties (cont.) Transactions with CIB